ACG Packaging Materials, a division of ACG – the world’s only integrated pharmaceutical solutions and manufacturing company, has been honoured with a Kepner-Tregoe (KT) Excellence Award in the team category ..read more

At a challenging time for the pharmaceutical industry, businesses are laser focussed on cost reduction and efficiency and are turning to third party suppliers for support. Sodexo, the global leader ..read more

The pharmaceutical industry is making remarkable progress in its quest for decarbonisation, with emissions already on a significant decline. Yet, the journey to net zero remains fraught with challenges, particularly ..read more

4D Medicine – a Nottingham-based company whose innovative biomaterial has potential to be used for a wide range of 3D printed implants and surgical devices – has raised £3.4m ($4.4m ..read more

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes. This medicine, a GLP-1 receptor agonist, was already approved for use in the treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioural support. The approval means that semaglutide is the first weight loss drug to be prescribed to prevent cardiovascular events, such as cardiovascular death, non-fatal heart attack and non-fatal st ..read more

Astellas Institute for Regenerative Medicine (AIRM), Universal Cells, and Osaka University have entered into a research collaboration to develop innovative pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease. Universal Cells holds the rights to Universal Donor Cell (UDC) technology to create cell therapy products from pluripotent stem cells that have reduced risk of immune rejection by genetically modifying Human Leukocyte Antigen (HLA) using gene editing technology. Under the terms of the agreement, the three parties aim ..read more

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first generic raltegravir medicines to treat adult and paediatric HIV patients who weigh at least 40kg. The Human Immunodeficiency Virus (HIV) causes Acquired Immune Deficiency Syndrome (AIDS). HIV produces an enzyme called HIV integrase which enables multiplication of the virus in cells within the body. Raltegravir stops this enzyme from working, and when used with other medicines it may reduce the amount of HIV in the patient’s blood and increase the patient’s CD4-cell count (a type of white blood cell that ..read more

Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced the designation as Regenerative Medicine Advanced Therapy (RMAT) by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of patients suffering from refractory stiff-person syndrome. “Stiff-person syndrome has devastating and life-altering effects on patients suffering from this rare autoimmune disease,” said Aman ..read more

Genomics plc, a healthcare company transforming health through the power of genomics, has announced a three-year extension of the company’s collaboration with Vertex Pharmaceuticals to use human genetics and machine learning to improve the discovery and development of new precision medicines. The partnership, which began in 2018, was previously extended in 2021. The collaboration will now run until 2026. The companies have been working together to support Vertex’s efforts to develop transformative medicines for serious diseases. To date, Genomics’ work has focused on using improved understand ..read more

Bayer AG and Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have been granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinson’s disease, by the United States (U.S.) Food and Drug Administration (FDA). AB-1005 has also been awarded the Innovation Passport, the United Kingdom Medicines and Healthcare products Regulatory Agency (UK MHRA) innovative medicine designation, for the treatment of Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell li ..read more